Glimepiride; pioglitazone hydrochloride - Generic Drug Details

What are the generic sources for glimepiride; pioglitazone hydrochloride and what is the scope of freedom to operate?

Glimepiride; pioglitazone hydrochloride is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa and Chartwell Rx, and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Glimepiride; pioglitazone hydrochloride has fifty-nine patent family members in thirty-one countries.

Two suppliers are listed for this compound.

Summary for glimepiride; pioglitazone hydrochloride

International Patents:	59
US Patents:	2
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Clinical Trials:	20
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for glimepiride; pioglitazone hydrochloride
DailyMed Link:	glimepiride; pioglitazone hydrochloride at DailyMed

Recent Clinical Trials for glimepiride; pioglitazone hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	Phase 4
Kanazawa University	Phase 4
Kowa Company, Ltd.	Phase 4

See all glimepiride; pioglitazone hydrochloride clinical trials

Pharmacology for glimepiride; pioglitazone hydrochloride

Drug Class	Peroxisome Proliferator Receptor alpha Agonist Peroxisome Proliferator Receptor gamma Agonist Sulfonylurea Thiazolidinedione
Mechanism of Action	Peroxisome Proliferator-activated Receptor alpha Agonists Peroxisome Proliferator-activated Receptor gamma Agonists

Anatomical Therapeutic Chemical (ATC) Classes for glimepiride; pioglitazone hydrochloride

A10BB	Sulfonylureas
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

A10BG	Thiazolidinediones
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUETACT	Tablets	glimepiride; pioglitazone hydrochloride	30 mg/2 mg and 30 mg/4 mg	021925	1	2009-12-22

US Patents and Regulatory Information for glimepiride; pioglitazone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	AB	RX	Yes	Yes	8,071,130		Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	AB	RX	Yes	No	7,700,128		Y
Chartwell Rx	PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	201049-002	Jan 4, 2013	AB	RX	No	No
Chartwell Rx	PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	201049-001	Jan 4, 2013	AB	RX	No	No
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	AB	RX	Yes	Yes	7,700,128		Y
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	AB	RX	Yes	No	8,071,130		Y

Expired US Patents for glimepiride; pioglitazone hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	6,303,640
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	4,687,777
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	4,687,777
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	6,329,404
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	7,538,125
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	7,538,125
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-002	Jul 28, 2006	6,211,205

International Patents for glimepiride; pioglitazone hydrochloride

Country	Patent Number	Title	Estimated Expiration
China	101384251
South Korea	100952090
Norway	20083104
European Patent Office	1962811
Israel	174201	SOLID PREPARATION COMPRISING A PIOGLITAZONE LAYER AND A LAYER COMPRISINIG GLIMEPIRIDE AND POLYSORBATE 80
Australia	2006328328
Russian Federation	2359661	ТВЕРДЫЙ ПРЕПАРАТ (SOLID PREPARATION)

Glimepiride; pioglitazone hydrochloride Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Glimepiride and Pioglitazone Hydrochloride?

The global market for glimepiride and pioglitazone hydrochloride, two oral hypoglycemics used primarily for type 2 diabetes management, is driven by rising diabetes prevalence, patent expirations, and evolving treatment protocols. As of 2022, the combined market size exceeds $4 billion and is projected to grow at a CAGR of approximately 4% through 2030.

Key Market Drivers

• Increasing Diabetes Prevalence: The International Diabetes Federation estimates global diabetes cases reached 463 million in 2019, forecasted to rise to 700 million by 2045. This expansion fuels demand for oral antidiabetics like glimepiride and pioglitazone.

• Patent Expirations: Glimepiride's patent expired in advanced markets (e.g., US in 2019), leading to increased generic competition, pressure on prices, and broader accessibility. Pioglitazone's patent expired earlier in 2012 in most regions.

• Treatment Guidelines: Both drugs are recommended as second-line agents when metformin monotherapy fails, maintaining their presence in treatment algorithms.

• Generic Penetration: Highly genericized drugs experience increased volume sales but reduced profit margins, influencing revenue streams.

Market Challenges

• Safety Concerns: Pioglitazone faces regulatory scrutiny due to risks of bladder cancer and cardiovascular events, leading to usage restrictions in some regions.

• Competition: The rise of newer drug classes, such as SGLT2 inhibitors and GLP-1 receptor agonists, offers alternative therapies with superior safety profiles, impacting demand.

• Pricing Pressures: Reimbursement policies favor affordable generics, limiting pricing power for branded formulations.

What Is the Financial Trajectory for Glimepiride and Pioglitazone Hydrochloride?

The revenue path for these drugs indicates an initial growth phase post-approval, followed by stabilization or decline due to patent expirations and competitive pressures.

Revenue Trends and Projections

Year	Glimepiride Revenue (USD millions)	Pioglitazone Revenue (USD millions)	Notes
2020	1,850	1,200	Peak period; high patent protection
2022	1,600	950	Patent expirations in updated markets; generic entry
2025 (forecast)	1,350	700	Continued generic penetration; slow volume growth
2030 (projection)	1,200	600	Market saturation; competition with novel agents

Data sources: Industry reports (IQVIA, 2022), market analysis (EvaluatePharma, 2022).

Profitability and Investment Outlook

• Branded Formulations: Initially high margins, diminishing with patent expiry. Companies focus on lifecycle extensions, such as combination formulations.

• Generics: Lower margins but stable volume sales. Investment in manufacturing scale and cost reductions remains critical.

• Emerging Markets: Account for a growing share due to affordability and unmet demand. Companies may see opportunities in low-cost formulations.

• R&D Funding: Limited investment in new formulations, shifting focus to combination therapies or biomarkers to differentiate.

How Do Regulatory and Policy Factors Impact Markets?

• FDA and EMA: Willingness to approve new formulations or biosimilars affects market expansion.

• Risk Management: Safety warnings, such as those for pioglitazone, influence prescribing behaviors and reimbursement.

• Price Controls: Governments impose price caps, especially in Europe and Asia, constraining revenue growth.

What Are the Strategic Implications?

• Generic Competition: Strategies include innovation in delivery (e.g., once-daily formulations) and combination products.

• Emerging Markets Focus: Rapidly growing markets present opportunities despite price sensitivity.

• Brand Differentiation: Emphasize safety profiles, ease of use, and combination options to sustain market share.

Key Takeaways

• The market for glimepiride and pioglitazone hydrochloride is characterized by revenue decline in mature markets due to patent expirations and competition from new drugs.

• Growth persists in emerging markets driven by affordability and rising diabetes prevalence.

• Regulation and safety concerns heavily influence market dynamics and product positioning.

• Companies reducing R&D investments in traditional formulations shift focus toward combination therapies and biosimilars.

• The overall outlook suggests declining revenues in established markets but steady opportunities in developing regions.

FAQs

1. Will glimepiride remain relevant in diabetes treatment?
Yes, especially in markets where cost-effective options are essential. Its role as a second-line therapy persists, but competition from newer agents may limit growth.

2. How does pioglitazone's safety profile affect its market?
Safety concerns, particularly regarding bladder cancer, have led to usage restrictions in some countries, limiting its market potential.

3. Are there efforts to develop new formulations of these drugs?
Limited; focus is on combination therapies and biosimilars rather than entirely new formulations, due to patent expirations.

4. What is the outlook for generic manufacturers?
Strong presence due to low entry barriers; margins are squeezed but volume sales remain substantial, especially in emerging markets.

5. How do newer drug classes influence these markets?
Classes like SGLT2 inhibitors and GLP-1 receptor agonists offer improved safety and efficacy, posing competitive threats to traditional drugs.

---

Citations
[1] IQVIA, "Global Diabetes Market Report," 2022.
[2] EvaluatePharma, "Global Pharmaceutical Forecast," 2022.
[3] International Diabetes Federation, Diabetes Atlas, 2019.